MedTrace Logo

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

NCT04740580 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-06-10

No results posted yet for this study

Summary

Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.

Conditions

  • Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

Glycine

The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)

DIETARY_SUPPLEMENT

N-acetylcysteine

The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)

DIETARY_SUPPLEMENT

Alanine

The placebo arm will supplement Alanine

Sponsors & Collaborators

  • The Methodist Hospital Research Institute

    collaborator OTHER

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Rajagopal V Sekhar, M.D. · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2026-04-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04740580 on ClinicalTrials.gov